Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Dolutegravir monotherapy of simian immunodeficiency virus-infected macaques selects for several patterns of resistance mutations with variable virological outcomes.

Van Rompay KK, Hassounah S, Keele BF, Lifson JD, Ardeshir A, Watanabe J, Pham HT, Chertova E, Sowder R, Balzarini J, Mesplède T, Wainberg MA.

J Virol. 2018 Oct 31. pii: JVI.01189-18. doi: 10.1128/JVI.01189-18. [Epub ahead of print]

PMID:
30381490
2.

Correction: Treatment with native heterodimeric IL-15 increases cytotoxic lymphocytes and reduces SHIV RNA in lymph nodes.

Watson DC, Moysi E, Valentin A, Bergamaschi C, Devasundaram S, Fortis SP, Bear J, Chertova E, Bess J Jr, Sowder R, Venzon DJ, Deleage C, Estes JD, Lifson JD, Petrovas C, Felber BK, Pavlakis GN.

PLoS Pathog. 2018 Oct 11;14(10):e1007345. doi: 10.1371/journal.ppat.1007345. eCollection 2018 Oct.

3.

Site-Specific Glycosylation of Virion-Derived HIV-1 Env Is Mimicked by a Soluble Trimeric Immunogen.

Struwe WB, Chertova E, Allen JD, Seabright GE, Watanabe Y, Harvey DJ, Medina-Ramirez M, Roser JD, Smith R, Westcott D, Keele BF, Bess JW Jr, Sanders RW, Lifson JD, Moore JP, Crispin M.

Cell Rep. 2018 Aug 21;24(8):1958-1966.e5. doi: 10.1016/j.celrep.2018.07.080.

4.

Ultrasensitive Immunoassay for Simian Immunodeficiency Virus p27CA.

Swanstrom AE, Gorelick RJ, Wu G, Howell B, Vijayagopalan A, Shoemaker R, Oswald K, Datta SA, Keele BF, Del Prete GQ, Chertova E, Bess JW Jr, Lifson JD.

AIDS Res Hum Retroviruses. 2018 Nov;34(11):993-1001. doi: 10.1089/AID.2018.0075. Epub 2018 Jul 10.

PMID:
29869527
5.

Treatment with native heterodimeric IL-15 increases cytotoxic lymphocytes and reduces SHIV RNA in lymph nodes.

Watson DC, Moysi E, Valentin A, Bergamaschi C, Devasundaram S, Fortis SP, Bear J, Chertova E, Bess J Jr, Sowder R, Venzon DJ, Deleage C, Estes JD, Lifson JD, Petrovas C, Felber BK, Pavlakis GN.

PLoS Pathog. 2018 Feb 23;14(2):e1006902. doi: 10.1371/journal.ppat.1006902. eCollection 2018 Feb. Erratum in: PLoS Pathog. 2018 Oct 11;14(10):e1007345.

6.

Truncating the gp41 Cytoplasmic Tail of Simian Immunodeficiency Virus Decreases Sensitivity to Neutralizing Antibodies without Increasing the Envelope Content of Virions.

White E, Wu F, Chertova E, Bess J, Roser JD, Lifson JD, Hirsch VM.

J Virol. 2018 Jan 17;92(3). pii: e01688-17. doi: 10.1128/JVI.01688-17. Print 2018 Feb 1.

7.

Mapping the complete glycoproteome of virion-derived HIV-1 gp120 provides insights into broadly neutralizing antibody binding.

Panico M, Bouché L, Binet D, O'Connor MJ, Rahman D, Pang PC, Canis K, North SJ, Desrosiers RC, Chertova E, Keele BF, Bess JW Jr, Lifson JD, Haslam SM, Dell A, Morris HR.

Sci Rep. 2016 Sep 8;6:32956. doi: 10.1038/srep32956.

8.

Adoptive Transfer of Engineered Rhesus Simian Immunodeficiency Virus-Specific CD8+ T Cells Reduces the Number of Transmitted/Founder Viruses Established in Rhesus Macaques.

Ayala VI, Trivett MT, Barsov EV, Jain S, Piatak M Jr, Trubey CM, Alvord WG, Chertova E, Roser JD, Smedley J, Komin A, Keele BF, Ohlen C, Ott DE.

J Virol. 2016 Oct 14;90(21):9942-9952. Print 2016 Nov 1.

9.

Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques.

Li H, Wang S, Kong R, Ding W, Lee FH, Parker Z, Kim E, Learn GH, Hahn P, Policicchio B, Brocca-Cofano E, Deleage C, Hao X, Chuang GY, Gorman J, Gardner M, Lewis MG, Hatziioannou T, Santra S, Apetrei C, Pandrea I, Alam SM, Liao HX, Shen X, Tomaras GD, Farzan M, Chertova E, Keele BF, Estes JD, Lifson JD, Doms RW, Montefiori DC, Haynes BF, Sodroski JG, Kwong PD, Hahn BH, Shaw GM.

Proc Natl Acad Sci U S A. 2016 Jun 14;113(24):E3413-22. doi: 10.1073/pnas.1606636113. Epub 2016 May 31.

10.

Enhanced antagonism of BST-2 by a neurovirulent SIV envelope.

Matsuda K, Chen CY, Whitted S, Chertova E, Roser DJ, Wu F, Plishka RJ, Ourmanov I, Buckler-White A, Lifson JD, Strebel K, Hirsch VM.

J Clin Invest. 2016 Jun 1;126(6):2295-307. doi: 10.1172/JCI83725. Epub 2016 May 9.

11.

Recombinant human heterodimeric IL-15 complex displays extensive and reproducible N- and O-linked glycosylation.

Thaysen-Andersen M, Chertova E, Bergamaschi C, Moh ES, Chertov O, Roser J, Sowder R, Bear J, Lifson J, Packer NH, Felber BK, Pavlakis GN.

Glycoconj J. 2016 Jun;33(3):417-33. doi: 10.1007/s10719-015-9627-1. Epub 2015 Nov 12.

PMID:
26563299
12.

Generation and characterization of a SIVmac239 clone corrected at four suboptimal nucleotides.

Fennessey CM, Reid C, Lipkey L, Newman L, Oswald K, Piatak M Jr, Roser JD, Chertova E, Smedley J, Gregory Alvord W, Del Prete GQ, Estes JD, Lifson JD, Keele BF.

Retrovirology. 2015 Jun 16;12:49. doi: 10.1186/s12977-015-0175-3.

13.

Gp120 on HIV-1 Virions Lacks O-Linked Carbohydrate.

Stansell E, Panico M, Canis K, Pang PC, Bouché L, Binet D, O'Connor MJ, Chertova E, Bess J, Lifson JD, Haslam SM, Morris HR, Desrosiers RC, Dell A.

PLoS One. 2015 Apr 27;10(4):e0124784. doi: 10.1371/journal.pone.0124784. eCollection 2015.

14.

Autologous aldrithiol-2-inactivated HIV-1 combined with polyinosinic-polycytidylic acid-poly-L-lysine carboxymethylcellulose as a vaccine platform for therapeutic dendritic cell immunotherapy.

Miller E, Spadaccia M, Sabado R, Chertova E, Bess J, Trubey CM, Holman RM, Salazar A, Lifson J, Bhardwaj N.

Vaccine. 2015 Jan 3;33(2):388-95. doi: 10.1016/j.vaccine.2014.10.054. Epub 2014 Nov 15.

15.

Antifibrotic therapy in simian immunodeficiency virus infection preserves CD4+ T-cell populations and improves immune reconstitution with antiretroviral therapy.

Estes JD, Reilly C, Trubey CM, Fletcher CV, Cory TJ, Piatak M Jr, Russ S, Anderson J, Reimann TG, Star R, Smith A, Tracy RP, Berglund A, Schmidt T, Coalter V, Chertova E, Smedley J, Haase AT, Lifson JD, Schacker TW.

J Infect Dis. 2015 Mar 1;211(5):744-54. doi: 10.1093/infdis/jiu519. Epub 2014 Sep 22.

16.

Selection of unadapted, pathogenic SHIVs encoding newly transmitted HIV-1 envelope proteins.

Del Prete GQ, Ailers B, Moldt B, Keele BF, Estes JD, Rodriguez A, Sampias M, Oswald K, Fast R, Trubey CM, Chertova E, Smedley J, LaBranche CC, Montefiori DC, Burton DR, Shaw GM, Markowitz M, Piatak M Jr, KewalRamani VN, Bieniasz PD, Lifson JD, Hatziioannou T.

Cell Host Microbe. 2014 Sep 10;16(3):412-8. doi: 10.1016/j.chom.2014.08.003.

17.

Characterization and favorable in vivo properties of heterodimeric soluble IL-15·IL-15Rα cytokine compared to IL-15 monomer.

Chertova E, Bergamaschi C, Chertov O, Sowder R, Bear J, Roser JD, Beach RK, Lifson JD, Felber BK, Pavlakis GN.

J Biol Chem. 2013 Jun 21;288(25):18093-103. doi: 10.1074/jbc.M113.461756. Epub 2013 May 6.

18.

Comparative characterization of transfection- and infection-derived simian immunodeficiency virus challenge stocks for in vivo nonhuman primate studies.

Del Prete GQ, Scarlotta M, Newman L, Reid C, Parodi LM, Roser JD, Oswald K, Marx PA, Miller CJ, Desrosiers RC, Barouch DH, Pal R, Piatak M Jr, Chertova E, Giavedoni LD, O'Connor DH, Lifson JD, Keele BF.

J Virol. 2013 Apr;87(8):4584-95. doi: 10.1128/JVI.03507-12. Epub 2013 Feb 13.

19.

Circulating IL-15 exists as heterodimeric complex with soluble IL-15Rα in human and mouse serum.

Bergamaschi C, Bear J, Rosati M, Beach RK, Alicea C, Sowder R, Chertova E, Rosenberg SA, Felber BK, Pavlakis GN.

Blood. 2012 Jul 5;120(1):e1-8. doi: 10.1182/blood-2011-10-384362. Epub 2012 Apr 10.

20.

Restricted replication of xenotropic murine leukemia virus-related virus in pigtailed macaques.

Del Prete GQ, Kearney MF, Spindler J, Wiegand A, Chertova E, Roser JD, Estes JD, Hao XP, Trubey CM, Lara A, Lee K, Chaipan C, Bess JW Jr, Nagashima K, Keele BF, Macallister R, Smedley J, Pathak VK, Kewalramani VN, Coffin JM, Lifson JD.

J Virol. 2012 Mar;86(6):3152-66. doi: 10.1128/JVI.06886-11. Epub 2012 Jan 11.

21.

Effect of mutations in the human immunodeficiency virus type 1 protease on cleavage of the gp41 cytoplasmic tail.

Waheed AA, Ablan SD, Sowder RC, Roser JD, Schaffner CP, Chertova E, Freed EO.

J Virol. 2010 Mar;84(6):3121-6. doi: 10.1128/JVI.02002-09. Epub 2009 Dec 30.

22.

Cryoelectron tomography of HIV-1 envelope spikes: further evidence for tripod-like legs.

Zhu P, Winkler H, Chertova E, Taylor KA, Roux KH.

PLoS Pathog. 2008 Nov;4(11):e1000203. doi: 10.1371/journal.ppat.1000203. Epub 2008 Nov 14.

23.

The Mamu B 17-restricted SIV Nef IW9 to TW9 mutation abrogates correct epitope processing and presentation without loss of replicative fitness.

Minang JT, Trivett MT, Coren LV, Barsov EV, Piatak M Jr, Chertov O, Chertova E, Ott DE, Ohlen C.

Virology. 2008 May 25;375(1):307-14. doi: 10.1016/j.virol.2008.02.005. Epub 2008 Mar 6.

24.

Mutational analysis of the C-terminal gag cleavage sites in human immunodeficiency virus type 1.

Coren LV, Thomas JA, Chertova E, Sowder RC 2nd, Gagliardi TD, Gorelick RJ, Ott DE.

J Virol. 2007 Sep;81(18):10047-54. Epub 2007 Jul 18.

25.

HIV-1 escape from the entry-inhibiting effects of a cholesterol-binding compound via cleavage of gp41 by the viral protease.

Waheed AA, Ablan SD, Roser JD, Sowder RC, Schaffner CP, Chertova E, Freed EO.

Proc Natl Acad Sci U S A. 2007 May 15;104(20):8467-71. Epub 2007 May 4.

26.

Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions.

Xu H, Chertova E, Chen J, Ott DE, Roser JD, Hu WS, Pathak VK.

Virology. 2007 Apr 10;360(2):247-56. Epub 2006 Nov 28.

27.

Proteomic and biochemical analysis of purified human immunodeficiency virus type 1 produced from infected monocyte-derived macrophages.

Chertova E, Chertov O, Coren LV, Roser JD, Trubey CM, Bess JW Jr, Sowder RC 2nd, Barsov E, Hood BL, Fisher RJ, Nagashima K, Conrads TP, Veenstra TD, Lifson JD, Ott DE.

J Virol. 2006 Sep;80(18):9039-52.

28.

Distribution and three-dimensional structure of AIDS virus envelope spikes.

Zhu P, Liu J, Bess J Jr, Chertova E, Lifson JD, Grisé H, Ofek GA, Taylor KA, Roux KH.

Nature. 2006 Jun 15;441(7095):847-52. Epub 2006 May 24.

PMID:
16728975
29.
30.

HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization sensitivity.

Louder MK, Sambor A, Chertova E, Hunte T, Barrett S, Ojong F, Sanders-Buell E, Zolla-Pazner S, McCutchan FE, Roser JD, Gabuzda D, Lifson JD, Mascola JR.

Virology. 2005 Sep 1;339(2):226-38.

31.

Elimination of retroviral infectivity by N-ethylmaleimide with preservation of functional envelope glycoproteins.

Morcock DR, Thomas JA, Gagliardi TD, Gorelick RJ, Roser JD, Chertova EN, Bess JW Jr, Ott DE, Sattentau QJ, Frank I, Pope M, Lifson JD, Henderson LE, Crise BJ.

J Virol. 2005 Feb;79(3):1533-42.

32.

Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins.

Lifson JD, Rossio JL, Piatak M Jr, Bess J Jr, Chertova E, Schneider DK, Coalter VJ, Poore B, Kiser RF, Imming RJ, Scarzello AJ, Henderson LE, Alvord WG, Hirsch VM, Benveniste RE, Arthur LO.

AIDS Res Hum Retroviruses. 2004 Jul;20(7):772-87.

PMID:
15307924
33.

Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions.

Zhu P, Chertova E, Bess J Jr, Lifson JD, Arthur LO, Liu J, Taylor KA, Roux KH.

Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15812-7. Epub 2003 Dec 10.

34.

Quantitation of HLA class II protein incorporated into human immunodeficiency type 1 virions purified by anti-CD45 immunoaffinity depletion of microvesicles.

Trubey CM, Chertova E, Coren LV, Hilburn JM, Hixson CV, Nagashima K, Lifson JD, Ott DE.

J Virol. 2003 Dec;77(23):12699-709.

36.

Comprehensive investigation of the molecular defect in vif-deficient human immunodeficiency virus type 1 virions.

Gaddis NC, Chertova E, Sheehy AM, Henderson LE, Malim MH.

J Virol. 2003 May;77(10):5810-20.

37.

Elimination of protease activity restores efficient virion production to a human immunodeficiency virus type 1 nucleocapsid deletion mutant.

Ott DE, Coren LV, Chertova EN, Gagliardi TD, Nagashima K, Sowder RC 2nd, Poon DT, Gorelick RJ.

J Virol. 2003 May;77(10):5547-56.

38.

Sites, mechanism of action and lack of reversibility of primate lentivirus inactivation by preferential covalent modification of virion internal proteins.

Chertova E, Crise BJ, Morcock DR, Bess JW Jr, Henderson LE, Lifson JD.

Curr Mol Med. 2003 May;3(3):265-72. Review.

PMID:
12699362
39.

Whole inactivated SIV virion vaccines with functional envelope glycoproteins: safety, immunogenicity, and activity against intrarectal challenge.

Lifson JD, Piatak M Jr, Rossio JL, Bess J Jr, Chertova E, Schneider D, Kiser R, Coalter V, Poore B, Imming R, Desrosiers RC, Henderson LE, Arthur LO.

J Med Primatol. 2002 Aug;31(4-5):205-16.

PMID:
12390543
40.

Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus.

Chertova E, Bess JW Jr, Crise BJ, Sowder II RC, Schaden TM, Hilburn JM, Hoxie JA, Benveniste RE, Lifson JD, Henderson LE, Arthur LO.

J Virol. 2002 Jun;76(11):5315-25.

42.

Experimental determination and calculations of redox potential descriptors of compounds directed against retroviral zinc fingers: Implications for rational drug design.

Topol IA, McGrath C, Chertova E, Dasenbrock C, Lacourse WR, Eissenstat MA, Burt SK, Henderson LE, Casas-Finet JR.

Protein Sci. 2001 Jul;10(7):1434-45.

43.

Partial activation and induction of apoptosis in CD4(+) and CD8(+) T lymphocytes by conformationally authentic noninfectious human immunodeficiency virus type 1.

Esser MT, Bess JW Jr, Suryanarayana K, Chertova E, Marti D, Carrington M, Arthur LO, Lifson JD.

J Virol. 2001 Feb;75(3):1152-64.

44.

Alteration of zinc-binding residues of simian immunodeficiency virus p8(NC) results in subtle differences in gag processing and virion maturation associated with degradative loss of mutant NC.

Yovandich JL, Chertova EN, Kane BP, Gagliardi TD, Bess JW Jr, Sowder RC 2nd, Henderson LE, Gorelick RJ.

J Virol. 2001 Jan;75(1):115-24.

45.

Ubiquitination of HIV-1 and MuLV Gag.

Ott DE, Coren LV, Chertova EN, Gagliardi TD, Schubert U.

Virology. 2000 Dec 5;278(1):111-21.

46.

Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2.

Schubert U, Ott DE, Chertova EN, Welker R, Tessmer U, Princiotta MF, Bennink JR, Krausslich HG, Yewdell JW.

Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13057-62.

47.

Probing the topography of HIV-1 nucleocapsid protein with the alkylating agent N-ethylmaleimide.

Chertova EN, Kane BP, McGrath C, Johnson DG, Sowder RC 2nd, Arthur LO, Henderson LE.

Biochemistry. 1998 Dec 22;37(51):17890-7.

PMID:
9922156
48.
49.

Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: a candidate SIV vaccine.

Arthur LO, Bess JW Jr, Chertova EN, Rossio JL, Esser MT, Benveniste RE, Henderson LE, Lifson JD.

AIDS Res Hum Retroviruses. 1998 Oct;14 Suppl 3:S311-9.

PMID:
9814959
50.

Inactivation of human immunodeficiency virus type 1 infectivity with preservation of conformational and functional integrity of virion surface proteins.

Rossio JL, Esser MT, Suryanarayana K, Schneider DK, Bess JW Jr, Vasquez GM, Wiltrout TA, Chertova E, Grimes MK, Sattentau Q, Arthur LO, Henderson LE, Lifson JD.

J Virol. 1998 Oct;72(10):7992-8001.

Supplemental Content

Loading ...
Support Center